Biofrontera

Biofrontera Net Margin

The Net Profit Margin of Biofrontera (B8FK.DE) as of Nov 21, 2026 is -30.06 %. In the previous year, Net Profit Margin was -35.71 % — a change of -15.80% (higher).

Net Margin

-30.06 %

YoY

-15.80%

Last updated:

Net Profit Margin of Biofrontera is 2025 -30.06 % . Net Profit Margin of Biofrontera was 2024 -35.71 % . It decreases by -15.80% higher compared to the previous year.

Biofrontera's net margin stands at -30.1%, down from 131.1% several years earlier.

The Biofrontera Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-42.06 EUR
Jan 1, 2019
-23.53 EUR
Jan 1, 2020
-42.92 EUR
Jan 1, 2021
131.13 EUR
Jan 1, 2022
-171.60 EUR
Jan 1, 2023
-1.14 EUR
Jan 1, 2024
-35.71 EUR
Jan 1, 2025
-30.06 EUR
The Biofrontera Net Margin history
YEARNet MarginYoY
-30.06 %-15.80%
-35.71 %+3,020.51%
-1.14 %-99.33%
-171.60 %-230.87%
131.13 %-405.55%
-42.92 %+82.35%
-23.53 %-44.05%
-42.06 %-68.59%
-133.90 %-22.41%
-172.57 %-36.26%
-270.75 %-21.82%
-346.33 %+13,272.11%
-2.59 %+115.81%
-1.20 %-86.68%
-9.01 %-52.23%
-18.87 %+85.24%
-10.18 %-76.31%
-42.98 %-25.37%
-57.60 %+8.01%
-53.32 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Net Profit Margin of Biofrontera is -30.06 % in 2025.

Net Profit Margin of Biofrontera changed from -35.71 % to -30.06 %, representing a -15.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Biofrontera since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Biofrontera with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Biofrontera

All Key Metrics — Biofrontera